A trial looking at combining two treatments for cancer of the liver (TACE 2)

Please note - this trial is no longer recruiting patients. We hope to add results when they are available.

Cancer type:

Liver cancer




Phase 3

This trial is looking at combining a drug called sorafenib with another type of treatment called chemoembolisation to treat cancer that started in the liver (primary liver cancer). This trial is supported by Cancer Research UK.

More about this trial

Doctors use different treatments for liver cancer. One is by blocking the supply of oxygen and food that the cancer needs to grow. Doctors can do this by injecting small beads into the blood vessels near the cancer. The aim is to block the small blood vessels (embolisation). The beads can also deliver chemotherapy directly to the cancer. This is called chemoembolisation. Transarterial chemoembolisation (TACE) is a type of chemoembolisation used for liver cancer.

Sorafenib is a biological therapy called a tyrosine kinase inhibitor. Tyrosine kinase is a chemical messenger (an enzyme) that signals cancer cells to grow. Sorafenib blocks these signals.

Sorafenib can also work by blocking the growth of new blood vessels that supply the cancer with food and oxygen.

Researchers think that combining sorafenib with TACE may be better than TACE alone for treating liver cancer that cannot be removed by surgery.

The aims of this trial are to find out

  • If combining sorafenib with TACE is better than TACE alone
  • What are the side effects of combining sorafenib with TACE
  • How this combination affects quality of life

Who can enter

You can enter this trial if you

  • Have at least one area of primary cancer of the liver that can be seen on a scan
  • Have satisfactory blood test results
  • Have satisfactory heart test results
  • Are fully active and can do anything you would normally do, apart from heavy physical work (performance status 0, 1)
  • Are willing to use reliable contraception during treatment and for 3 months after if there is a chance you or your partner could become pregnant
  • Are at least 18 years old

You cannot enter this trial if you

  • Are able to have surgery to remove your cancer or liver transplant surgery
  • Have cancer that has spread outside your liver (stage 4)
  • Have already had treatment for your cancer, including radiotherapy, chemotherapy or beads put in to block the blood supply to the cancer (embolisation)
  • Have severe liver cirrhosis
  • Have fluid collected in your tummy (abdomen) that cannot be controlled by medication (doctors call this ‘ascites’)
  • Had problems with bleeding in the past 4 weeks
  • Have an infection
  • Are HIV positive
  • Are pregnant or breastfeeding

Trial design

This is a phase 3 trial. It will recruit 412 people throughout Europe. It is a randomised trial. You will be put into 1 of 2 treatment groups. Neither you nor your doctor can choose which group you are in or will know which group you are in. This is called a double blind trial.

If you are in group 1, you will have TACE and sorafenib.

If you are in group 2, you will have TACE and a dummy drug (placebo).

The beads used in this trial for TACE contain the chemotherapy drug doxorubicin.

You go to the X-ray department to have the doxorubicin beads put in place. First you have a local anaesthetic Open a glossary item injection into your groin to numb the area. The doctor puts a thin tube (catheter) into the largest blood vessel in your groin and threads it up to the artery that feeds the liver. Once they are sure that the catheter is in the right place, the doctors will inject the doxorubicin beads directly into your liver. The doctors will then remove the tube from your groin. The beads block the blood flow and deliver doxorubicin to the cancer.

Sorafenib and the dummy drug are tablets. You take them twice a day. You continue taking the tablets as long as they are helping you and the side effects are not too bad.

You will have a diary to write down when you take your tablets and any side effects you might have. You need to bring this with you every time you visit the hospital.

You will be asked to fill in a questionnaire

  • Before starting treatment
  • 1 week after having the beads put in
  • Every 6 weeks while having treatment

The questionnaire will ask you about any side effects you have and how you have been feeling. This is called a quality of life study. If you don’t want to take part in this study you don’t have to.  You can still take part in the trial.

Hospital visits

You will see the doctor and have some tests before you take part in this trial. These tests include

  • A physical examination
  • Blood tests
  • Heart trace (ECG Open a glossary item)
  • Heart scan (MUGA scan Open a glossary item or echocardiogram Open a glossary item)
  • CT scan or MRI scan

You see the doctor 1 week after having the beads put in and have the following tests

  • A physical examination
  • Blood tests
  • Heart trace

While on treatment you see the doctor every 6 weeks and have the following tests

  • A physical examination
  • Blood tests
  • Heart trace
  • CT scan or MRI scan – every other time

Side effects

The side effects of sorafenib can include

You cannot take some medications while having sorafenib because they could affect how it works.

Your doctor will talk to you about which medications you cannot take.

The side effects of doxorubicin can include

The side effects of having the beads put in (chemoembolisation) can include

  • Pain
  • Fever
  • Infection in the liver (abcess)

You can find more information about sorafenib, doxorubicin and chemoembolisation on CancerHelp UK.

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Professor Tim Meyer

Supported by

Biocompatibles UK Limited
Cancer Research UK
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer
University College London (UCL)

Other information

This is Cancer Research UK trial number CRUKE/08/022.

Questions about cancer? Contact our information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:


Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Wendy took part in a new trial studying the possible side effect of hearing loss

A picture of Wendy

"I was delighted to take part in a clinical trial as it has the potential to really help others in the future.”

Last reviewed:

Rate this page:

Currently rated: 3 out of 5 based on 1 vote
Thank you!
We've recently made some changes to the site, tell us what you think

Share this page